Skip to content

Precigen PGEN Net Investment in Lease

Net Investment in Lease at other companies

Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Arrowhead Research logo
Arrowhead ResearchARWR
PVL
Palvella TherapeuticsPVLA
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP

Other financials

Income statement

See full
Revenue$23.3M+1,634%
Operating income-$6.0M+73.5%
Net income-$7.9M+85.4%
EPS (diluted)-$0.02+88.9%

Balance sheet

See full
Cash & equivalents$7.5M+23.5%
Total debt$98.3M+1,714%
Total equity$20.2M+244%
Total assets$138.6M+7.6%

Cash flow

See full
Operating cash flow-$43.8M-168%
CapEx$258.0K-58.5%
Free cash flow-$44.1M-160%

Valuation

See full
Market cap$1.91B+213%
Enterprise value$2B+234%
P/S72×

Profitability

See full
Gross margin83.6%
Operating margin-2,890.9%
Net margin-3,656%
FCF margin-1,756.5%

Returns & leverage

See full
Return on equity-843.6%-1,103pp
Debt / equity4.9×
Current ratio4.8×+1.3×

Where this comes from

Reported directly by Precigen in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Precigen’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Precigen's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Precigen's net investment in lease?
Precigen (PGEN) reported net investment in lease of $4.37M in Q1 2026.
How has Precigen's net investment in lease changed year-over-year?
Precigen's net investment in lease decreased by 13.8% year-over-year, from $5.07M to $4.37M.
What is the long-term trend for Precigen's net investment in lease?
Over 5 years (2020 to 2025), Precigen's net investment in lease has grown at a -12.9% compound annual growth rate (CAGR), from $9.35M to $4.68M.